Your Enterprise's Cognitive Twin
Wilbur is a synthetic pharmaceutical enterprise—thousands of AI coworkers mapped to every function of your organization, from Global Regulatory Lead to Clinical Development VP. It runs in parallel to your real enterprise, executing scenario simulations at machine speed.
A new way to think in pharma. Driven not by bandwidth, but by possibility.
"De-risk transformation. Simulate before you execute."
Average
Typical development timeline from discovery to approval
Drug candidates that ultimately achieve regulatory approval
The "Complexity Ceiling" is Real
Modern pharmaceutical enterprises have become too complex for the human mind to model alone. With thousands of employees, intricate R&D pipelines, and rapidly evolving AI tools, the number of variables exceeds cognitive capacity. This is why 70% of transformation initiatives fail.
Traditional consulting delivers static PowerPoints that are obsolete the moment they're delivered. Internal AI initiatives fare no better—70% of pharma digital projects fail to deliver real outcomes, and 89% of companies still revert to Excel for critical work.
Enterprise Cognition Engine
Wilbur is not a tool. It is the first scaled attempt to simulate, run, test, and refine the behavior of a pharmaceutical company—in full strategic, functional, and operational fidelity.
Thousands of synthetic coworkers, each mapped to a defined domain role and governed by resume-driven execution protocols. These are not LLMs run wild, but structured agents bound by domain-specific job specs and methodological boundaries.
Synthetic Coworkers
Thousands of AI agents mapped to real pharma roles—from Global Regulatory Lead to Payer Strategy Director—interact, negotiate, and surface insights no single analyst could find.
Failure Fingerprints
Our proprietary algorithms identify specific patterns that lead to failure, allowing you to generate 'Exclusion Lists' of what NOT to do.
Stop Condition™
Executive-grade bounded insights. We don't just give you data; we give you clear Go/No-Go signals based on your risk tolerance.
Enterprise-Scale Speed
What takes consulting firms months of interviews and manual analysis, Wilbur delivers in hours. Run thousands of scenarios continuously.
Beyond Consulting. Beyond Internal AI.
vs. Global Consulting
$2-5M per function, $300-500M for enterprise transformation
~$10-20M license replaces hundreds of millions in fees. Always-on simulation vs. static reports.
vs. Internal AI
70% of pharma digital projects fail. Build vs. buy paralysis.
Pre-built pharma-native agents at global scale. Sidesteps internal inertia and politics.
vs. Point Solutions
Fragmented vendor landscape with overlapping, incompatible offerings.
Model-agnostic orchestration that integrates best-in-class components and swaps underperformers continuously.
Built for the Pharma C-Suite
Designed specifically for the complexities of Top-20 Global Pharmaceutical firms.
CEO
Enterprise transformation requires $300M+ consulting engagements with uncertain ROI
Run the transformation in simulation first; commit capital only to validated strategies
CFO
Cannot model the true cost of organizational change before committing resources
Simulate financial outcomes of restructuring scenarios before execution
COO
Operational inefficiencies compound during restructuring, delaying time-to-market
Identify bottlenecks and optimize cross-functional workflows in real-time
Chief Strategy Officer
Uncertainty in M&A integration success and portfolio prioritization
Simulate integration scenarios and portfolio decisions before signing
Chief Digital Officer
Unmanaged AI tool proliferation creating operational friction
Map and optimize AI workflows across silos with synthetic coworkers
Head of R&D
Pipeline decisions lack visibility into downstream organizational capacity
Model R&D portfolio scenarios against resource constraints and timelines